Singapore-based MiRXES has announced that it is providing the ID3EAL miRNA and other non-coding RNA detection technology to Beth Israel Deaconess Medical Center (BIDMC) – a teaching hospital of the Harvard Medical School (HMS) – and their recently opened Non-Coding RNA Precision Diagnostics and Therapeutics Core Facility to promote scientific and research collaboration to advance translational research and therapeutic applications in RNA medicine.

Hosted by the Cancer Center at BIDMC, the Core Facility is led by the HMS Initiative for RNA Medicine (HIRM), which brings together leading investigators in RNA biology & medicine to accelerate investigations into how non-coding RNA functions and how these insights can be used to develop new therapies.

“This collaboration will enhance our ability to provide state-of-the-art methods for detection, quantification and discovery of ncRNAs,” said Dr. Frank Slack, Director of the HIRM, “This will propel our researchers’ efforts to examine the genome for novel biomarkers and targets for therapeutics. We are tremendously excited about the potential benefit for patients.”

“Liquid biopsy is the new frontier in cancer diagnosis, patient stratification and response monitoring,” stated Dr. Lihan Zhou, co-founder and CEO of MiRXES. “miRNA and other non-coding RNAs carry information unique from that of ctDNA and protein markers and can be quantified from as low as 0.1 ml of biofluids. Our work with Beth Israel Deaconess Medical Center therefore marks the continuation of our journey to develop innovative, actionable and affordable miRNA assays for early detection of major cancers and other devastating diseases, to improve patient prognosis and reduce healthcare cost.”